<DOC>
	<DOC>NCT02158403</DOC>
	<brief_summary>The purpose of this study is to assess how often blood clots form in the FDA-approved HeartMateÂ® II (HM II) Left Ventricular Assist Device (LVAD) and to identify risks related to clotting within the pump.</brief_summary>
	<brief_title>PREVENtion of HeartMate II Pump Thrombosis</brief_title>
	<detailed_description>PREVENT is a prospective, multi-center, non-randomized study that is designed (1) to assess the incidence of HM II pump thrombosis in the current era when recommended practices for clinical management are adopted, and (2) to identify the risk factors associated with pump thrombosis events. The recommended practices are focused on implantation technique, anticoagulation regimen, pump speed and blood pressure management. All consecutive patients receiving a HM II implant will be considered for this study.</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<criteria>Subject or legally authorized representative has signed an informed consent form Subject is receiving the HeartMate II as their first Left Ventricular Assist Device (LVAD) Prior mechanical circulatory support (MCS) (except for intraaortic balloon pump) Participation in any other clinical investigation(s) involving a MCS device, or an investigation(s) that is likely to confound study results or affect study outcome</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>HeartMate II</keyword>
	<keyword>heart assist device</keyword>
	<keyword>pump thrombosis</keyword>
	<keyword>hypercoagulable disorder</keyword>
	<keyword>thrombus</keyword>
	<keyword>Thoratec Corporation</keyword>
</DOC>